BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28504904)

  • 1. Application of Panel-Based Tests for Inherited Risk of Cancer.
    Shah PD; Nathanson KL
    Annu Rev Genomics Hum Genet; 2017 Aug; 18():201-227. PubMed ID: 28504904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
    Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
    Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
    Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
    Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
    Piccinin C; Panchal S; Watkins N; Kim RH
    Expert Rev Anticancer Ther; 2019 Sep; 19(9):787-801. PubMed ID: 31469018
    [No Abstract]   [Full Text] [Related]  

  • 6. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
    Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
    Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening.
    Frey MK; Kim SH; Bassett RY; Martineau J; Dalton E; Chern JY; Blank SV
    Gynecol Oncol; 2015 Nov; 139(2):211-5. PubMed ID: 26296696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
    Frey MK; Sandler G; Sobolev R; Kim SH; Chambers R; Bassett RY; Martineau J; Sapra KJ; Boyd L; Curtin JP; Pothuri B; Blank SV
    Gynecol Oncol; 2017 Jul; 146(1):123-128. PubMed ID: 28495237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical testing with a panel of 25 genes associated with increased cancer risk results in a significant increase in clinically significant findings across a broad range of cancer histories.
    Rosenthal ET; Bernhisel R; Brown K; Kidd J; Manley S
    Cancer Genet; 2017 Dec; 218-219():58-68. PubMed ID: 29153097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
    Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L
    Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inherited Cancer in the Age of Next-Generation Sequencing.
    Price KS; Svenson A; King E; Ready K; Lazarin GA
    Biol Res Nurs; 2018 Mar; 20(2):192-204. PubMed ID: 29325452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients.
    Lincoln SE; Kobayashi Y; Anderson MJ; Yang S; Desmond AJ; Mills MA; Nilsen GB; Jacobs KB; Monzon FA; Kurian AW; Ford JM; Ellisen LW
    J Mol Diagn; 2015 Sep; 17(5):533-44. PubMed ID: 26207792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.
    Judkins T; Leclair B; Bowles K; Gutin N; Trost J; McCulloch J; Bhatnagar S; Murray A; Craft J; Wardell B; Bastian M; Mitchell J; Chen J; Tran T; Williams D; Potter J; Jammulapati S; Perry M; Morris B; Roa B; Timms K
    BMC Cancer; 2015 Apr; 15():215. PubMed ID: 25886519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
    Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G
    J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germ-line variants identified by next generation sequencing in a panel of estrogen and cancer associated genes correlate with poor clinical outcome in Lynch syndrome patients.
    Jóri B; Kamps R; Xanthoulea S; Delvoux B; Blok MJ; Van de Vijver KK; de Koning B; Oei FT; Tops CM; Speel EJ; Kruitwagen RF; Gomez-Garcia EB; Romano A
    Oncotarget; 2015 Dec; 6(38):41108-22. PubMed ID: 26517685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing.
    Kluska A; Balabas A; Paziewska A; Kulecka M; Nowakowska D; Mikula M; Ostrowski J
    BMC Med Genomics; 2015 May; 8():19. PubMed ID: 25948282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of laboratory perspectives on hereditary cancer panels.
    Stoll J; Weissman SM; Hook N; Selkirk C; Johnson AK; Newlin A; Vogel Postula KJ
    Fam Cancer; 2016 Oct; 15(4):689-96. PubMed ID: 26869169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-gene Panel Testing in Breast Cancer Management.
    Fountzilas C; Kaklamani VG
    Cancer Treat Res; 2018; 173():121-140. PubMed ID: 29349761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.